People
Industry analysts were shocked when in July the FDA reversed course on Amicus’ Phase III treatment for Fabry disease.
Boehringer’s global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018.
Bruno Strigini, the CEO of Novartis Oncology, plans to exit the company’s Executive Committee by Dec. 31, 2017, and leave entirely in early 2018.
Four months after Jeff Huber stepped down as CEO of GRAIL, the company has tapped his replacement.
Tango officially launched in 2017 and hit the ground running as a cancer drug target discovery and drug development company based on CRISPR technology.
Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.
The French executive made the public apology after he was castigated by SAGIP Rep. Rodante Marcoleta for his company’s “insensitivity” to the concerns of the Filipino public.
Prelude Fertility was founded in late 2016 by successful startup entrepreneur Martin Varsavsky with a $200M investment.
Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage.
PRESS RELEASES